Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLA-mismatched microtransplantation (39aaaa)
- Development stage
- Unknown
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HLA-mismatched microtransplantation (MST) is a form of allogeneic cellular therapy in which granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells from an HLA-mismatched donor are infused into a patient following conventional chemotherapy. Unlike traditional allogeneic stem cell transplantation, MST does not result in permanent engraftment of donor cells and does not require immunosuppression because it avoids graft-versus-host disease (GVHD). The approach aims to harness the graft-versus-leukemia/tumor effect while minimizing toxicity and complications associated with full engraftment. MST is primarily investigated for hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic-phase chronic myeloid leukemia (CP-CML), non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and severe aplastic anemia. The procedure extends donor availability by allowing use of mismatched donors and has shown promise in improving relapse-free survival without increasing GVHD risk[1][2][3][4][5][6].
- Other names
- HLA-mismatched stem cell microtransplantationHLA-mismatched allogeneic cellular therapy
Beyond the preview
Go deeper on HLA-mismatched microtransplantation (39aaaa).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLA-mismatched microtransplantation (39aaaa).